Cambridge Healthtech Institute’s 10th Annual

Oligonucleotide Discovery & Delivery

Optimizing Design and Advances in the Clinic

March 11-12, 2025

Cambridge Healthtech Institute’s Oligonucleotide Discovery & Delivery conference reveals the latest strategies at the forefront of discovery, chemistry, and delivery. Recent preclinical and clinical advances in the field will be discussed in depth, along with novel delivery mechanisms. Industry and academic experts present detailed case studies on RNAi, antisense, aptamers, conjugates, and more, paving the way for the next generation of targeted oligonucleotide therapeutics.

Coverage will include, but is not limited to:

Developments from early discovery through to late-stage clinical programs
Advances in RNA editing
Novel therapeutic GalNAc platforms
Implementation of AI and machine learning in oligonucleotide design
Adoption of innovative technologies used in discovery and delivery
Big pharma perspective on oligos and DNA/RNA editing
Strategic collaboration among big pharma, small biotechs, and academia
Examining the safety and toxicity of nucleic acids
Advances in the following areas, including but not limited to: the CNS, the liver, inhalation drugs, immuno oncology, and ocular diseases

The deadline for priority consideration is August 23^rd, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: